SCOTTSDALE, Ariz. – October 30, 2026 -- LifeStance Health (Nasdaq: LFST) reports that 74% of its patients with treatment-resistant depression achieved a clinically meaningful reduction in symptoms after 12 weeks of esketamine (Spravato), while 61% of TMS patients improved after at least 30 sessions. The outpatient mental healthcare provider is expanding access to both specialty services across the U.S.
Esketamine analysis covers 258 patients and shows suicidal ideation falling to 2%
LifeStance tracked progress with the Patient Health Questionnaire (PHQ-9). It defines clinically meaningful improvement as a score reduction of five or more points.
Among the 258 esketamine patients, the share reporting suicidal ideation nearly every day fell from 13% before treatment to 2% afterward, an 85% reduction.
TMS analysis of 355 patients records suicidal ideation dropping from 13% to 6%
The TMS group showed a 50% reduction in near-daily suicidal ideation, from 13% to 6%. The 61% response rate refers to patients who completed at least 30 treatment sessions.
LifeStance describes both analyses as observational. It says they describe only the patients included and do not guarantee individual outcomes.
LifeStance estimates 139,000 adult patients had treatment-resistant depression last year
The company puts the figure at 28% of all its patients with depression and roughly 14% of the more than one million patients it serves annually. Nationally, treatment-resistant depression affects about 30% of people diagnosed with major depressive disorder, or 2.8 million people, according to a study in The Journal of Clinical Psychiatry cited by LifeStance.
Patients with the condition spend an average of 571 days in a depressive episode, according to the company.
Treatment protocols define the care delivery model
Esketamine is an FDA-approved nasal spray administered in person under clinician supervision. It is typically given twice weekly for four weeks, followed by weekly or every-other-week maintenance. TMS is an FDA-approved, non-invasive brain stimulation therapy, often used after patients have tried multiple antidepressants and psychotherapy without sufficient relief.
"Not finding relief from previous treatments does not mean they are out of options," said Dr. Stephanie Eken, Chief Medical Officer of LifeStance Health. She said the company is committed to expanding access to these services.
LifeStance and its supported practices employ approximately 8,500 clinicians and operate across 35 states and more than 550 centers. The new analyses follow earlier 2026 reports on depression and anxiety outcomes among more than 180,000 patients, and on outcomes across generations and geographic regions.